Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, on Wednesday released first quarter financial results, and provided updates on therapies currently in the pipeline.
The company specializes in manufacturing T-cell engaging (TCE) bispecific antibodies targeting solid tumors to treat a number of cancer types.
Q1 2026:
The company recorded a net loss of $8.68 million, or $0.09 per share in Q1 2026, while in the same period of 2025, the net loss was $4.57 million, or $0.05 per share.
Other income was reported at $0.66 million, up from an income of $0.95 million in the first quarter of 2025.
Research and development expenses (R&D) were $7.01 million, compared to $3.46 million in the previous year.
Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $545.53 million.
Pipeline Highlights:
The company is currently developing its lead program for CTIM-76, a CLDN6 x CD3 TCE bispecific antibody for the treatment of platinum-resistant ovarian cancer. CTIM-76 is under a Phase 1a trial, with interim data expected in June 2026.
The company received approval from the human research ethics committee (HREC) and a clinical trial notification (CTN) acknowledgment from the Australian therapeutic goods administration (TGA) to begin a first-in-human Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 TCE bispecific antibody,
CT-202 has shown potential in treating bladder, colorectal, breast, and lung cancers in preclinical studies. Preclinical data was presented at the annual meeting of the American Association of Cancer Research (AACR), and the company plans to advance a first-in-human clinical study for CT-202 later this year.
Context also anticipates the release of Phase 1a clinical data for CT-95, a MSLN x CD3 bispecific antibody, by September 2026.
CNTX closed Wednesday at $2.41, down 1.23%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.